ASCO 2025 | SUPRAME: a PRAME-specific TCR-T cell therapy in cutaneous melanoma
Jason Luke, MD, FACP, FASCO, UPMC Hillman Cancer Center, Pittsburgh, PA, gives an overview of the Phase III SUPRAME trial (NCT06743126), which evaluates the efficacy of IMA203, a PRAME-specific T cell receptor T cell therapy (TCR-T) cell therapy, in pretreated unresectable or metastatic cutaneous melanoma. This randomized study will be the first in solid tumors to assess a cellular therapy against investigator’s choice in patients and will assess progression-free survival as the primary endpoint. IMA203 has shown promising early results in melanoma and unlike tumor infiltrating lymphocytes, lower doses of interleukin-2 are needed. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
